Solana (SOL) has surged past $155 on the back of rising speculation about a potential spot ETF approval. While the excitement ...

Rhythm Pharmaceuticals' potential first-in-class HO drug, strong pipeline, and limited competition offer blockbuster potential. Click to read why RYTM is a Buy.

Readers have been peppering us with questions about Labor’s proposed tax on super balances above $3 million. Here are three.